News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01

23 June 2022

OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021

25 March 2022

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

11 March 2022

OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

31 January 2022

OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

27 January 2022

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

14 January 2022

Sign up for the latest News & Events

Events & Presentations

ERS – 9-13 September 2017 Milan

1 September 2017

BIO USA – San Diego 19-22 June 2017

1 June 2017

ATS – Washington 19-24 May 2017

1 May 2017
This site is registered on wpml.org as a development site.